You are here: Industry Insights > Market News > Yemen to get more COVID-19 vaccines by end of month - health ministry

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

CBZ-L-Valganciclovir

4-Bromo-3-nitroanisole

PF-680Adjustable Cellophane Tri-dimensiona Overwrapping Machine (with tear type)

2-Chlorophenothiazine

Flibanserin

its control software

Yemen to get more COVID-19 vaccines by end of month - health ministry

firstwordpharmaJuly 19, 2021

Tag: COVID-19 , Vaccines , Covax

Favorites

Yemen expects to get a second batch of COVID-19 vaccine by the end of this month through the COVAX global vaccine-sharing scheme, as reported National Post on Sunday.

Yemen to get more COVID-19 vaccines by end of month - health ministry

The health ministry said that Yemen is expecting to receive 151,000 doses of the Johnson & Johnson vaccine, out of an eventual total of 504,000, while another batch of AstraZeneca's vaccine doses is expected via COVAX in August.

Previous:To Combat COVID-19 Vaccine Hesitancy in Black Community, Twin Sister Doctors Develop Strategy

Next:British ministers decide against mass vaccination for teens - The Telegraph

InnoCare Announces Approval of Clinical Trial of a Novel ADC ICP-B794 in China

PharmaSourcesJuly 04, 2025

InnoCare Pharmaannounced the approval of the Investigational New Drug (IND) by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) to conduct the clinical trial of a novel B7-H3 targeted ADC ICP-B794.

CanSinoBIO Launches Pneumococcal Vaccine: An Innovative Choice to Safeguard Children's Health

ACN NewswireJune 20, 2025

LTS and Nualtis Announce Strategic Cooperation to Expand Global Manufacturing Capabilities, Accelerate Market Expansion, and Ensure Customer Success

PR NewswireJune 25, 2025

Yemen to get more COVID-19 vaccines by end of month - health ministry | Pharmasources.com

Hua Medicine Announces at 2025 ADA Scientific Sessions that Dorzagliatin Combined With DPP-4 Inhibitor Shows Promise in Reducing Blood Lipids While Restoring Glucose Homeosta

ACN NewswireJune 23, 2025

Hua Medicine announced today that the Company presented the latest research results of dorzagliatin, its global first-in-class glucokinase activator (GKA), at the 85th Scientific Sessions of the American Diabetes Association (ADA).

久久婷婷国产综合精品,久久久久久久性潮,换脸国产av一区二区三区,韩国精品一区二区三区无码视频 ,久久久久成人精品无码

Yemen to get more COVID-19 vaccines by end of month - health ministry

Related News

InnoCare Announces Approval of Clinical Trial of a Novel ADC ICP-B794 in China

CanSinoBIO Launches Pneumococcal Vaccine: An Innovative Choice to Safeguard Children's Health

LTS and Nualtis Announce Strategic Cooperation to Expand Global Manufacturing Capabilities, Accelerate Market Expansion, and Ensure Customer Success

Hua Medicine Announces at 2025 ADA Scientific Sessions that Dorzagliatin Combined With DPP-4 Inhibitor Shows Promise in Reducing Blood Lipids While Restoring Glucose Homeosta

You may like
More>>

久久婷婷国产综合精品,久久久久久久性潮,换脸国产av一区二区三区,韩国精品一区二区三区无码视频 ,久久久久成人精品无码

Yemen to get more COVID-19 vaccines by end of month - health ministry

Related News

InnoCare Announces Approval of Clinical Trial of a Novel ADC ICP-B794 in China

CanSinoBIO Launches Pneumococcal Vaccine: An Innovative Choice to Safeguard Children's Health

LTS and Nualtis Announce Strategic Cooperation to Expand Global Manufacturing Capabilities, Accelerate Market Expansion, and Ensure Customer Success

Hua Medicine Announces at 2025 ADA Scientific Sessions that Dorzagliatin Combined With DPP-4 Inhibitor Shows Promise in Reducing Blood Lipids While Restoring Glucose Homeosta

You may likeMore>>

You may like
More>>